Biogen Inc Stock Analysis
BIIB Stock | USD 204.76 0.06 0.03% |
Biogen Inc is undervalued with Real Value of 237.86 and Target Price of 330.76. The main objective of Biogen stock analysis is to determine its intrinsic value, which is an estimate of what Biogen Inc is worth, separate from its market price. There are two main types of Biogen's stock analysis: fundamental analysis and technical analysis.
The Biogen stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Biogen's ongoing operational relationships across important fundamental and technical indicators.
Biogen |
Biogen Stock Analysis Notes
About 93.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.88. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biogen Inc recorded earning per share (EPS) of 7.92. The entity had not issued any dividends in recent years. The firm had 3:1 split on the 18th of January 2001. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 9610 people. For more info on Biogen Inc please contact Christopher Viehbacher at 617 679 2000 or go to https://www.biogen.com.Biogen Inc Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biogen's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biogen Inc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Biogen Inc generated a negative expected return over the last 90 days | |
Biogen Inc has a poor financial position based on the latest SEC disclosures | |
Over 93.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from kalkinemedia.com: Neuroregeneration Therapy Market Set to Witness Astonishing Growth 2024-2031 Biogen Inc, Pfizer Inc, Sanofi S.A, AbbVie |
Biogen Inc Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biogen previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
13th of February 2024 Upcoming Quarterly Report | View | |
23rd of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
13th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Biogen Largest EPS Surprises
Earnings surprises can significantly impact Biogen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2000-07-18 | 2000-06-30 | 0.08 | 0.09 | 0.01 | 12 | ||
1999-04-20 | 1999-03-31 | 0.03 | 0.04 | 0.01 | 33 | ||
1999-02-09 | 1998-12-31 | 0.04 | 0.05 | 0.01 | 25 |
Biogen Environmental, Social, and Governance (ESG) Scores
Biogen's ESG score is a quantitative measure that evaluates Biogen's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Biogen's operations that may have significant financial implications and affect Biogen's stock price as well as guide investors towards more socially responsible investments.
Biogen Thematic Classifications
In addition to having Biogen stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
![]() | Hedge FavoritesInvestment assets that are popular or favored by hedge funds |
Biogen Stock Institutional Investors
Shares | T. Rowe Price Associates, Inc. | 2024-03-31 | 1.6 M | Beutel, Goodman & Company Ltd. | 2024-03-31 | 1.6 M | Clearbridge Advisors, Llc | 2024-03-31 | 1.6 M | Legal & General Group Plc | 2024-03-31 | 1.6 M | Northern Trust Corp | 2024-03-31 | 1.4 M | Dimensional Fund Advisors, Inc. | 2024-03-31 | 1.3 M | Bank Of New York Mellon Corp | 2024-06-30 | 1.2 M | Deutsche Bank Ag | 2024-03-31 | 1.1 M | Pictet Asset Manangement Sa | 2024-03-31 | 1 M | Vanguard Group Inc | 2024-03-31 | 16.6 M | Primecap Management Company | 2024-03-31 | 16.2 M |
Biogen Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 29.84 B.Biogen Profitablity
The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.33 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.33.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.09 | 0.08 | |
Return On Capital Employed | 0.06 | 0.08 | |
Return On Assets | 0.04 | 0.06 | |
Return On Equity | 0.08 | 0.10 |
Management Efficiency
Biogen Inc has return on total asset (ROA) of 0.0519 % which means that it generated a profit of $0.0519 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0763 %, meaning that it created $0.0763 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.06, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 102.28 | 107.39 | |
Tangible Book Value Per Share | 1.50 | 1.43 | |
Enterprise Value Over EBITDA | 16.83 | 17.67 | |
Price Book Value Ratio | 2.53 | 2.40 | |
Enterprise Value Multiple | 16.83 | 17.67 | |
Price Fair Value | 2.53 | 2.40 | |
Enterprise Value | 6.4 B | 4.2 B |
The analysis of Biogen's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Biogen's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Biogen Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Operating Margin 0.325 | Profit Margin 0.1198 | Beta (0.04) | Return On Assets 0.0519 | Return On Equity 0.0763 |
Technical Drivers
As of the 31st of August, Biogen shows the Risk Adjusted Performance of (0.02), standard deviation of 1.73, and Mean Deviation of 1.32. Biogen Inc technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Biogen Inc Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Biogen middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Biogen Inc. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Biogen Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biogen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Singhal Priya over three months ago Disposition of tradable shares by Singhal Priya of Biogen at 213.09 subject to Rule 16b-3 | ||
Ginger Gregory over three months ago Disposition of 634 shares by Ginger Gregory of Biogen at 240.98 subject to Rule 16b-3 | ||
Douglas Williams over a year ago Sale by Douglas Williams of 916 shares of Biogen |
Biogen Outstanding Bonds
Biogen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biogen Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biogen bonds can be classified according to their maturity, which is the date when Biogen Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
US09061GAH48 Corp BondUS09061GAH48 | View | |
MPLX LP 4875 Corp BondUS55336VAG59 | View | |
CVS Health Corp Corp BondUS126650DE72 | View | |
BIOGEN INC 52 Corp BondUS09062XAD57 | View | |
BIOGEN INC 405 Corp BondUS09062XAF06 | View | |
BIOGEN INC Corp BondUS09062XAG88 | View | |
BIOGEN INC Corp BondUS09062XAH61 | View | |
BIIB 325 15 FEB 51 Corp BondUS09062XAK90 | View |
Biogen Predictive Daily Indicators
Biogen intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biogen stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Biogen Corporate Filings
13A | 16th of August 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 14th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 7th of August 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 1st of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 25th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
20th of June 2024 Other Reports | ViewVerify | |
F4 | 3rd of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
26th of April 2024 Other Reports | ViewVerify |
Biogen Forecast Models
Biogen's time-series forecasting models are one of many Biogen's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biogen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Biogen Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Biogen prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biogen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Biogen. By using and applying Biogen Stock analysis, traders can create a robust methodology for identifying Biogen entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.13 | 0.14 | |
Operating Profit Margin | 0.13 | 0.14 | |
Net Profit Margin | 0.12 | 0.12 | |
Gross Profit Margin | 0.74 | 0.51 |
Current Biogen Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biogen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biogen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
330.76 | Strong Buy | 35 | Odds |
Most Biogen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biogen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biogen Inc, talking to its executives and customers, or listening to Biogen conference calls.
Biogen Stock Analysis Indicators
Biogen Inc stock analysis indicators help investors evaluate how Biogen stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biogen shares will generate the highest return on investment. By understating and applying Biogen stock analysis, traders can identify Biogen position entry and exit signals to maximize returns.
Begin Period Cash Flow | 3.4 B | |
Long Term Debt | 6.8 B | |
Common Stock Shares Outstanding | 145.6 M | |
Total Stockholder Equity | 14.8 B | |
Tax Provision | 135.3 M | |
Quarterly Earnings Growth Y O Y | -0.017 | |
Property Plant And Equipment Net | 3.7 B | |
Cash And Short Term Investments | 1 B | |
Cash | 1 B | |
Accounts Payable | 403.3 M | |
Net Debt | 6.3 B | |
50 Day M A | 215.7196 | |
Total Current Liabilities | 3.4 B | |
Other Operating Expenses | 8 B | |
Non Current Assets Total | 20 B | |
Forward Price Earnings | 14.2857 | |
Non Currrent Assets Other | 284.3 M | |
Stock Based Compensation | 264.2 M |
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |